Patients' clinical data
| Clinical characteristics . | Patients with deletions (n = 23) . | Patients without deletions (n = 163) . | Pvalues . |
|---|---|---|---|
| Sex (M/F) (%) | 60/40 | 61/39 | (Fisher exact test) |
| 1 | |||
| Median age, y (range) | 47 (15-64) | 51 (22-86) | (Wilcoxon rank sum test) |
| .042 | |||
| Peripheral blood prognostic markers* | (Wilcoxon rank sum test) | ||
| Hemoglobin (g/L) | 105.1 ± 26.5 | 116.2 ± 23.7 | .085 |
| White blood cell count (×109) | 181.8 ± 174.1 | 120.3 ± 143.3 | .057 |
| Platelet count (×109) | 768.3 ± 504.0 | 447.4 ± 369.3 | .003 |
| Basophils (%) | 2.4 ± 3.0 | 4.6 ± 3.9 | .039 |
| Blasts (%) | 1.0 ± 1.4 | 2.5 ± 5.2 | .107 |
| No. (%) of patients with poor prognostic markers† | 0 (0%) | 1 (1.9%) | 1.0 |
| Cytogenetics findings (%) | n = 23 | n = 126 | (χ2test) |
| Standard Ph translocation | 74 | 87 | .04 |
| Variant Ph translocation | 17 | 4 | |
| Additional abnormalities | 9 | 9 | |
| Type of treatment (%) | (χ2 test) | ||
| Chemotherapy alone | 18 | 28 | .6 |
| Chemotherapy and interferon | 4 | 8 | |
| Interferon alone | 26 | 22 | |
| BMT‡ | 52 | 42 | |
| Duration of chronic phase2-153 | n = 11 | n = 95 | (log-rank test) |
| 25 mo | 96 mo | .005 | |
| Relapse rate following BMT (%) | n = 12 | n = 58 | (Fisher exact test) |
| 41 | 3.4 | < .001 | |
| Survival time | 36 mo | 84 mo | (log-rank test) |
| .005 |
| Clinical characteristics . | Patients with deletions (n = 23) . | Patients without deletions (n = 163) . | Pvalues . |
|---|---|---|---|
| Sex (M/F) (%) | 60/40 | 61/39 | (Fisher exact test) |
| 1 | |||
| Median age, y (range) | 47 (15-64) | 51 (22-86) | (Wilcoxon rank sum test) |
| .042 | |||
| Peripheral blood prognostic markers* | (Wilcoxon rank sum test) | ||
| Hemoglobin (g/L) | 105.1 ± 26.5 | 116.2 ± 23.7 | .085 |
| White blood cell count (×109) | 181.8 ± 174.1 | 120.3 ± 143.3 | .057 |
| Platelet count (×109) | 768.3 ± 504.0 | 447.4 ± 369.3 | .003 |
| Basophils (%) | 2.4 ± 3.0 | 4.6 ± 3.9 | .039 |
| Blasts (%) | 1.0 ± 1.4 | 2.5 ± 5.2 | .107 |
| No. (%) of patients with poor prognostic markers† | 0 (0%) | 1 (1.9%) | 1.0 |
| Cytogenetics findings (%) | n = 23 | n = 126 | (χ2test) |
| Standard Ph translocation | 74 | 87 | .04 |
| Variant Ph translocation | 17 | 4 | |
| Additional abnormalities | 9 | 9 | |
| Type of treatment (%) | (χ2 test) | ||
| Chemotherapy alone | 18 | 28 | .6 |
| Chemotherapy and interferon | 4 | 8 | |
| Interferon alone | 26 | 22 | |
| BMT‡ | 52 | 42 | |
| Duration of chronic phase2-153 | n = 11 | n = 95 | (log-rank test) |
| 25 mo | 96 mo | .005 | |
| Relapse rate following BMT (%) | n = 12 | n = 58 | (Fisher exact test) |
| 41 | 3.4 | < .001 | |
| Survival time | 36 mo | 84 mo | (log-rank test) |
| .005 |
Ph indicates Philadelphia chromosome; BMT, bone marrow transplant.
Patients who were referred to the center after the treatment was initiated were censored from the peripheral blood prognostic markers study. For the rest of the patients (patients with deletions n = 16, patients without deletions n = 51), laboratory values were obtained at the diagnosis. Values are mean ± SD.
The presence at diagnosis of peripheral blood blasts (15%), peripheral blood basophils (20%), or thrombocytopenia < 100 × 109/L has been identified as features with independent adverse prognostic significance.54 55
One syngeneic transplantation was done in the group of patients with deletions, for the rest of the patients from both groups allogeneic transplantations were done.
Patients who underwent BMT were censored from the duration of chronic-phase study.